Complex metabolic disharmony in PMM2-CDG paves the way to new therapeutic approaches
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
37245379
DOI
10.1016/j.ymgme.2023.107610
PII: S1096-7192(23)00240-8
Knihovny.cz E-resources
- Keywords
- CDG-Ia, Congenital disorders of glycosylation, Fibroblasts, OMICS, PMM2-CDG, Therapeutic ideas,
- MeSH
- Amino Acids metabolism MeSH
- Phosphotransferases (Phosphomutases) * genetics deficiency MeSH
- Glycosylation MeSH
- Humans MeSH
- Lipids MeSH
- Congenital Disorders of Glycosylation * genetics therapy metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Amino Acids MeSH
- Phosphotransferases (Phosphomutases) * MeSH
- Lipids MeSH
PMM2-CDG is the most common defect among the congenital disorders of glycosylation. In order to investigate the effect of hypoglycosylation on important cellular pathways, we performed extensive biochemical studies on skin fibroblasts of PMM2-CDG patients. Among others, acylcarnitines, amino acids, lysosomal proteins, organic acids and lipids were measured, which all revealed significant abnormalities. There was an increased expression of acylcarnitines and amino acids associated with increased amounts of calnexin, calreticulin and protein-disulfid-isomerase in combination with intensified amounts of ubiquitinylated proteins. Lysosomal enzyme activities were widely decreased as well as citrate and pyruvate levels indicating mitochondrial dysfunction. Main lipid classes such as phosphatidylethanolamine, cholesterol or alkyl-phosphatidylcholine, as well as minor lipid species like hexosylceramide, lysophosphatidylcholines or phosphatidylglycerol, were abnormal. Biotinidase and catalase activities were severely reduced. In this study we discuss the impact of metabolite abnormalities on the phenotype of PMM2-CDG. In addition, based on our data we propose new and easy-to-implement therapeutic approaches for PMM2-CDG patients.
References provided by Crossref.org